Illinois Institute of Technology
Chicago, Illinois, 60616, United States
Location status: Recruiting
Location contact
Chelsea Preiss, MS
CONTACT
Indika Edirisinghe, PhD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07650682
This observational study aims to collect detailed metabolic and physiologic data from adults with insulin-dependent type 2 diabetes mellitus following consumption of a mixed meal tolerance test. Participants will undergo frequent blood sampling over a 4-hour period after consuming a standardized liquid mixed meal to measure glucose, insulin, glucagon, C-peptide, and triglyceride responses. Participants will also use continuous glucose monitoring and wearable physical activity tracking devices during free-living conditions.
The purpose of this study is to develop mathematical models and digital representations ("digital twins") of people with type 2 diabetes mellitus. These models may help researchers better understand metabolic responses to meals, physical activity, and diabetes treatments, and may support future development of personalized diabetes technologies and therapies.
Interested in participating?
Request Info18 year–65 year
All sexes
Observational
Chicago, Illinois, 60616, United States
Location status: Recruiting
Chelsea Preiss, MS
CONTACT
Indika Edirisinghe, PhD
PRINCIPAL_INVESTIGATOR
Participants will first complete a screening visit at the Clinical Nutrition Research Center (CNRC) at the Illinois Institute of Technology. Screening procedures include assessment of medical history, dietary habits, physical activity history, body measurements, vital signs, glycated hemoglobin (HbA1c), and evaluation of eligibility criteria. Eligible participants will receive a continuous glucose monitor (CGM) and wearable activity tracker and will complete dietary recall assessments during the outpatient monitoring period.
Participants will undergo approximately 8 days of outpatient monitoring using continuous glucose monitoring and wearable physical activity tracking devices during free-living conditions. During this period, participants will continue their usual diabetes management and daily activities while recording dietary intake and medication use.
Participants will then complete an in-clinic Liquid Meal Test (LMT) visit following an overnight fast. During the study-day visit, an indwelling intravenous catheter will be placed for repeated venous blood collection. Blood samples will be collected before and over a 4-hour period after consumption of a standardized liquid meal consisting of vanilla-flavored Ensure®. Plasma measurements will include glucose, insulin, glucagon, C-peptide, and triglycerides. Participants will remain seated and monitored throughout the study visit, and safety assessments will be performed before discharge.
The information collected from continuous glucose monitoring, wearable activity tracking, dietary assessments, and repeated blood sampling will be used to develop mathematical models capable of simulating physiologic and metabolic responses in individuals with insulin-dependent type 2 diabetes mellitus. These models may contribute to future research focused on personalized diabetes management, optimization of therapeutic strategies, and evaluation of diabetes technologies.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: -10 to 240 minutes relative to meal consumption
Plasma glucose concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a clinical chemistry analyzer (Randox). Unit of Measure: mg/dL
Time frame: -10 to 240 minutes relative to meal consumption
Plasma insulin concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a clinical chemistry analyzer (Randox). Unit of Measure: (µIU/mL)
Time frame: -10 to 240 minutes relative to meal consumption
Plasma glucagon concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a multiplex immunoassay platform (Luminex). Unit of Measure: pg/mL
Time frame: -10 to 240 minutes relative to meal consumption
Plasma C-peptide concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a multiplex immunoassay platform (Luminex).
Unit of Measure: ng/mL
Time frame: -10 to 240 minutes relative to meal consumption
Plasma triglyceride concentrations will be measured from venous blood samples collected at baseline and multiple postprandial time points using a clinical chemistry analyzer (Randox).
Unit of Measure: mg/dL
Time frame: Approximately 8 days during outpatient monitoring
Interstitial Glucose Concentration during Free-Living Conditions via Continuous Glucose Monitor Description: Interstitial glucose concentration measured continuously during outpatient free-living conditions using the Dexcom G7 continuous glucose monitoring device.
Unit of Measure: mg/dL
Time frame: Approximately 8 days during outpatient monitoring.
Average daily step count, reported in steps per day, measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
Time frame: Approximately 8 days during outpatient monitoring.
Average daily active minutes, reported in minutes per day, measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
Time frame: Approximately 8 days during outpatient monitoring.
Average sleep duration, reported in hours per night, measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
Time frame: Approximately 8 days during outpatient monitoring.
Average resting heart rate, reported in beats per minute (bpm), measured during outpatient free-living conditions using the Fitbit Sense 2 wearable activity tracker.
Time frame: Approximately 8 days during outpatient monitoring
To assess dietary intake and nutritional patterns using self-reported ASA24 dietary recall assessments during the outpatient monitoring period.
Contact information is provided by the study sponsor or research team.
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Mathematical Modeling of Type 2 Diabetes Mellitus
Acronym: MT2D
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06899191
Autoimmune Diseases, Diabetes Mellitus
New Brunswick, New Jersey, United States
View Trial DetailsNCT05463289
Autoimmune Diseases, Cardiovascular Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT07011147
Autoimmune Diseases, Diabetes
Aurora, Colorado, United States
View Trial DetailsNCT06815081
Autoimmune Diseases, Diabetes Mellitus
Cardiff, United Kingdom
View Trial Details